Preclinical Oncology Imaging & Radiopharmaceuticals for Drug Development

Your Partner for Preclinical and Translational Oncology Imaging

Perceptive Discovery delivers advanced preclinical oncology imaging and radiopharmaceutical development services to support therapeutic programs from discovery through early clinical development. Our cross-disciplinary team of radiochemists, imaging scientists, and oncology pharmacologists, work collaboratively to de-risk discovery and early-phase development by visualizing images of anti-tumor efficacy, target engagement, pharmacokinetics, dosimetry and therapeutic biodistribution in clinically relevant tumor models.

With deep expertise in radiopharmaceuticals and radioligand therapy (RLT), we help clients design and validate custom-labeled agents, quantify tumor uptake, and predict human dose and safety profiles—accelerating the path from concept to clinic.

A Proven Leader in Preclinical Oncology Imaging

• 11,000+ studies completed across imaging modalities
• Full suite of multi-modality imaging for oncology research: PET, SPECT, MRI, CT, bioluminescence (BLI), fluorescence (FLI), and cryofluorescence tomography (CFT)
• Specialized in radiopharmaceutical therapies, Antibody Drug Conjugates (ADCs), CAR-Ts, small molecules, and oncolytic viruses
• Experts in disease relevant in vivo tumor models including syngeneic, CDX, and orthotopic models
• Global infrastructure with 7 preclinical labs and 4 radiochemistry centers

De-risk and Accelerate Your Oncology & RLT Pipeline

Radioligand Therapy & Theranostic Imaging

Support your RLT program with comprehensive imaging and dosimetry services. We design studies using diagnostic/therapeutic isotope pairs (e.g., Zr-89/Lu-177 or Pb-203/Pb-212) to evaluate biodistribution, tumor targeting, and normal tissue dose.

• Surrogate isotope imaging to project human dosimetry
• Alpha and beta emitter experience (Ac-225, Lu-177, Pb-212, At-211)
• Personalized imaging strategies for patient selection and IND submission readiness

Theranostic Agent Development

Design and validate companion imaging agents for patient stratification and dose prediction using isotopes like F-18, Ga-68, Cu-64, and Zr-89.

Cell & Gene Therapy Tracking

Visualize CAR-T, oncolytic virus, and engineered cell biodistribution in real time using bioluminescence and advanced radiolabeling.

Efficacy in In Vivo Tumor Models

Quantify efficacy in disease-relevant models to increase translational confidence and guide candidate selection.

Advanced Image Analysis

Gain fast, actionable insights through automated data processing pipelines—supporting segmentation, dosimetry, PK/PD evaluation, and therapeutic response modeling.

Figure 1: Perceptive radiolabeled the DOTA-conjugate with both
In-111 for SPECT imaging and Ac-225 for targeted alpha-therapy.